Drugs / Talarozole
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT00725439 | Sep 2004 → Jul 2005 | acne | Stiefel, a GSK Company | Completed | No outcome recorded |
| Phase 2 | NCT00725348 | Apr 2004 → Mar 2005 | psoriasis | Stiefel, a GSK Company | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT00719121 Comparator | Nov → Dec 2006 | dermatitis | Stiefel, a GSK Company | Completed | No outcome recorded |
| Phase 2 | NCT00716144 Comparator | Jun 2006 → May 2007 | psoriasis | Stiefel, a GSK Company | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Talarozole | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00716144 ↗ |
| Known as | R-115866 | ChEMBL registry synonym — accepted as the source's own label CHEMBL459505 ↗ |
| Known as | Rambazole | ChEMBL registry synonym — accepted as the source's own label CHEMBL459505 ↗ |
| Known as | Talarozol | ChEMBL registry synonym — accepted as the source's own label CHEMBL459505 ↗ |
| Action | Inhibit | “Cytochrome P450 26A1 inhibitor” CHEMBL459505 ↗ |
| Modality | Small molecule | — CHEMBL459505 ↗ |
| Route | Oral | “Oral Capsule Once Daily” NCT00716144 ↗ |
| Target | CYP26A1 | “Cytochrome P450 26A1 inhibitor” CHEMBL459505 ↗ |